202 related articles for article (PubMed ID: 18070218)
1. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.
Kóbori L; Kõhalmy K; Porrogi P; Sárváry E; Gerlei Z; Fazakas J; Nagy P; Járay J; Monostory K
Br J Clin Pharmacol; 2008 Mar; 65(3):428-36. PubMed ID: 18070218
[TBL] [Abstract][Full Text] [Related]
2. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
3. Homogenous phenomenon of graft liver CYP2C19 genotypes after living donor liver transplantation.
Chiu KW; Nakano T; Hu TH; Tseng HP; Cheng YF; Jawan B; Eng HL; Goto S; Chen CL
Eur J Clin Invest; 2012 Apr; 42(4):352-6. PubMed ID: 21913914
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 in living donor liver transplantation.
Chiu KW; Nakano T; Chen KD; Hsu LW; Lai CY; Huang CY; Cheng YF; Goto S; Chen CL
J Biomed Sci; 2015 May; 22(1):32. PubMed ID: 25975271
[TBL] [Abstract][Full Text] [Related]
5. Western blotting analysis for quantitative detection of CYP2C19 expression in liver tissues in the setting of living donor liver transplantation.
Chiu KW; Nakano T; Tseng HP; Cheng YF; Jawan B; Eng HL; Goto S; Chen CL
Hepatogastroenterology; 2012 May; 59(115):805-8. PubMed ID: 22469723
[TBL] [Abstract][Full Text] [Related]
6. Update: genetic polymorphism of drug metabolizing enzymes in humans.
Tanaka E
J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
[TBL] [Abstract][Full Text] [Related]
7. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
Yamazaki H
Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
[TBL] [Abstract][Full Text] [Related]
8. The Genotype Frequency of CYP2C19 Enzyme after Liver Transplantation.
Badiee P; Hashemizadeh Z; Malek-Hosseini SA; Geramizadeh B
Int J Organ Transplant Med; 2019; 10(2):93-98. PubMed ID: 31285806
[TBL] [Abstract][Full Text] [Related]
9. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
10. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
13. Genetically determined differences in drug metabolism as a risk factor in drug toxicity.
Eichelbaum M; Kroemer HK; Mikus G
Toxicol Lett; 1992 Dec; 64-65 Spec No():115-22. PubMed ID: 1471165
[TBL] [Abstract][Full Text] [Related]
14. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Tanaka E; Kurata N; Yasuhara H
J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic cytochromes P450 and drugs used in psychiatry.
Coutts RT; Urichuk LJ
Cell Mol Neurobiol; 1999 Jun; 19(3):325-54. PubMed ID: 10319191
[TBL] [Abstract][Full Text] [Related]
17. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.
Donato MT; Lahoz A; Jiménez N; Pérez G; Serralta A; Mir J; Castell JV; Gómez-Lechón MJ
Drug Metab Dispos; 2006 Sep; 34(9):1556-62. PubMed ID: 16763015
[TBL] [Abstract][Full Text] [Related]
18. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
